Chiral inversion and hydrolysis of thalidomide: Mechanisms and catalysis by bases and serum albumin, and chiral stability of teratogenic metabolites

Chemical Research in Toxicology

Volumn 11, Issue 12, 1998, Pages 1521-1528

  Reist, Marianne ^a   Carrupt, Pierre Alain ^a   Francotte, Eric ^b   Testa, Bernard ^a  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ARGININE; LYSINE; SERUM ALBUMIN; THALIDOMIDE;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CATALYSIS; CHIRALITY; DRUG HYDROLYSIS; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOMODULATION; LEPROSY; NAUSEA; NEUROTOXICITY; SEDATION; TERATOGENICITY;

ALGORITHMS; AMINO ACIDS; BIOTRANSFORMATION; BUFFERS; CATALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHATES; SERUM ALBUMIN; STEREOISOMERISM; TERATOGENS; THALIDOMIDE;

EID: 0032411785     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx9801817     Document Type: Article

References (2)

1. Mellin, G. W., and Katzenstein, M. (1962) The saga of thalidomide: neuropathy to embryopathy, with case reports and congenital anomalies. N. Engl. J. Med. 267, 1184-1244.
2. De Camp, W. H. (1989) The FDA perspective on the development of stereoisomers. Chirality 1, 2-6.